430
Participants
Start Date
August 31, 1998
Primary Completion Date
September 30, 2001
Study Completion Date
June 30, 2005
WBRT
3 GY of WBRT daily for a total of 10 days
MGd
5.0 mg /kg MGd plus WBRT
Memorial Sloan-Kettering Cancer Center, New York
Presbyterian-University Hospital, Pittsburgh
Mercy Hospital Cancer Center - Scranton, Scranton
Abington Hematology Oncology Associates, Meadowbrook
Kimmel Cancer Center of Thomas Jefferson University - Philadelphia, Philadelphia
Emory Clinic, Atlanta
Charlotte County Radiation Therapy Regional Center, Port Charlotte
Thompson Cancer Survival Center, Knoxville
Cleveland Clinic Taussig Cancer Center, Cleveland
Barrett Cancer Center, The University Hospital, Cincinnati
Barbara Ann Karmanos Cancer Institute, Detroit
Harper Hospital and Wayne State University, Detroit
Medical College of Wisconsin, Milwaukee
University of Wisconsin Comprehensive Cancer Center, Madison
Veterans Affairs Medical Center - Minneapolis, Minneapolis
Hematology and Oncology Services - Metairie, Metairie
Scott and White Memorial Hospital, Temple
University of Colorado Cancer Center, Denver
New Mexico Oncology-Hematology, Albuquerque
Kaiser Permanente Medical Group, Los Angeles
Beckman Research Institute, City of Hope, Los Angeles
Marin Oncology Associates, Inc., Greenbrae
Radiation Oncology Center - Sacramento, Sacramento
Virginia Mason Medical Center, Seattle
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles
Indiana University Cancer Center, Indianapolis
Massachusetts General Hospital Cancer Center, Boston
North Memorial Research Center, Minneapolis
Cancer Institute of New Jersey, New Brunswick
Vanderbilt Cancer Center, Nashville
University of Texas - MD Anderson Cancer Center, Houston
Cross Cancer Institute, Edmonton
Cancer Care Ontario-Hamilton Regional Cancer Centre, Hamilton
Princess Margaret Hospital, Toronto
Montreal General Hospital, Montreal
Lead Sponsor
Pharmacyclics LLC.
INDUSTRY